Advertisement

Topics

Nuclear Factor Erythroid 2 Related Factor 2 HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500

11:07 EDT 21 Jun 2017 | BioPortfolio Report Blog

Nuclear Factor Erythroid 2 Related Factor 2 HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 Pipeline Review, H1 2017

Summary

Nuclear Factor Erythroid 2 Related Factor 2 HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 Nuclear factor erythroidderived 2like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated upregulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the betaglobin cluster by mediating enhancer activity of hypersensitive site 2 of the betaglobin locus control region.

Nuclear Factor Erythroid 2 Related Factor 2 HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 pipeline Target constitutes close to 36 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 4, 13 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 8 and 3 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Metabolic Disorders, Cardiovascular, Ophthalmology, Toxicology, Infectious Disease, Respiratory, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Inflammation, Multiple Sclerosis, Psoriasis, Friedreich Ataxia, Type 2 Diabetes, Amyotrophic Lateral Sclerosis, Cardiomyopathy, Chagas Disease American Trypanosomiasis, Chronic Obstructive Pulmonary Disease COPD, Diabetic Complications, Diabetic Nephropathy, Medulloblastoma, Neuroblastoma, Radiodermatitis, Systemic Sclerosis Scleroderma, Type 1 Diabetes Juvenile Diabetes, Age Related Macular Degeneration, AIDS Associated Dementia, Alport Syndrome, Alzheimer's Disease, Atherosclerosis, Breast Cancer, Cardiovascular Disease, Cerebral Vasospasm, Chronic Kidney Disease Chronic Renal Failure, Corneal Degeneration, Encephalomyelitis, Huntington Disease, Idiopathic Pulmonary Hypertension, Ischemia Reperfusion Injury, Metastatic Breast Cancer, Metastatic Melanoma, Mitochondrial Diseases, Neuro Muscular Disorders, Neurodegenerative Diseases, NonHodgkin Lymphoma, NonSmall Cell Lung Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, PostMyocardial Infarction, Primary Progressive Multiple Sclerosis PPMS, Prostate Cancer, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Radiation Injury, Relapsing Remitting Multiple Sclerosis RRMS, Retinal Degeneration, Retinopathy, Subarachnoid Hemorrhage and Ulcerative Colitis.

The latest report Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Review, H1 2017, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2
The report reviews Nuclear Factor Erythroid 2 Related Factor 2 HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 targeted therapeutics and enlists all their major and minor projects
The report assesses Nuclear Factor Erythroid 2 Related Factor 2 HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Nuclear Factor Erythroid 2 Related Factor 2 HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Nuclear Factor Erythroid 2 Related Factor 2 HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Stress
Stress is caused by your perception of situations around you and then the reaction of your body to them. The automatic stress response to unexpected events is known as 'fight or flight'. Discovered by Walter Cannon in 1932, it is the release of h...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...